AUTOIMMUNE DISEASES OF DIGESTIVE SYSTEM

Cover Page
  • Authors: Ivashkin V.T.1, Sheptulina A.F.1, Raikhel'son K.L.2, Losik E.A.1, Ivashkin K.V.1, Okhlobystin A.V.1, Baranskaya E.K.1, Polyektova E.A.1, Shifrin O.S.1
  • Affiliations:
    1. I.M. Sechenov First Moscow State Medical University, Russian Federation
    2. I.I. Mechnikov North-Western State Medical University, Saint-Petersburg, Russian Federation
  • Issue: Vol 70, No 2 (2015)
  • Pages: 139-151
  • Section: PROCEEDINGS of the GENERAL MEETING of the Department of Medical Sciences, RAS
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/49
  • DOI: https://doi.org/10.15690/vramn.v70.i2.1306

Abstract


Autoimmune diseases of digestive system refer to pathological conditions, caused by autoimmune mechanisms, and their etiology remains unknown. This is a group of relatively rare diseases, however, during the last years a marked tendency towards the raise in incidence and prevalence is observed, which led to an increase in number of clinical investigations on etiology, pathogenesis, and, accordingly, development of new diagnostic methods and therapies. Results of such trials shown, for example, that the pathogenesis of chronic cholestatic liver diseases is associated with nuclear receptors function, while the main etiological and pathogenic factor of inflammatory bowel diseases represents gut microbiota. Despite new achievements in autoimmune diseases of digestive system research, therapies are low effective and are accompanied by a huge number of adverse events. The fact that these diseases may lead to malignant tumors is also worth noting. For example, patients with primary sclerosing cholangitis have a 160 times higher risk of cholangiocellular carcinoma, while 10–14% of patients with celiac disease may develop malignancies of esophagus, small and large intestine. Thus, these diseases require further investigation with a purpose of more accurate diagnostic methods for the detection of disease at early stages and new effective and safe therapies development.

 


V. T. Ivashkin

I.M. Sechenov First Moscow State Medical University, Russian Federation

Author for correspondence.
Email: 2135833@mail.ru

Russian Federation

доктор медицинских наук, профессор, академик РАН, заведующий кафедрой про-
педевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. Сеченова
Адрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1, тел.: +7 (499) 248-35-91

A. F. Sheptulina

I.M. Sechenov First Moscow State Medical University, Russian Federation

Email: sheptulina.anna@gmail.com

Russian Federation

аспирант кафедры пропедевтики внутренних болезней лечебного факультета Первого
МГМУ им. И.М. Сеченова
Адрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1

K. L. Raikhel'son

I.I. Mechnikov North-Western State Medical University, Saint-Petersburg, Russian Federation

Email: kraikhelson@mail.ru

Russian Federation

кандидат медицинских наук, доцент кафедры гастроэнтерологии и диетологии
СЗГМУ им. И.И. Мечникова
Адрес: 197110, Санкт-Петербург, пр. Динамо, д. 3

E. A. Losik

I.M. Sechenov First Moscow State Medical University, Russian Federation

Email: kollezion@yandex.ru

Russian Federation

аспирант кафедры пропедевтики внутренних болезней лечебного факультета
Первого МГМУ им. И.М. Сеченова
Адрес:119991, Москва, ул. Погодинская, д. 1, стр. 1

K. V. Ivashkin

I.M. Sechenov First Moscow State Medical University, Russian Federation

Email: 2135833@mail.ru

Russian Federation

кандидат медицинских наук, ассистент кафедры пропедевтики внутренних
болезней лечебного факультета Первого МГМУ им. И.М. Сеченова
Адрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1

A. V. Okhlobystin

I.M. Sechenov First Moscow State Medical University, Russian Federation

Email: okhlobystin@mail.ru

Russian Federation

кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней
лечебного факультета Первого МГМУ им. И.М. Сеченова
Адрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1

E. K. Baranskaya

I.M. Sechenov First Moscow State Medical University, Russian Federation

Email: ebaranskaya@yandex.ru

Russian Federation

доктор медицинских наук, профессор кафедры пропедевтики внутренних
болезней лечебного факультета Первого МГМУ им. И.М. Сеченова
Адрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1

E. A. Polyektova

I.M. Sechenov First Moscow State Medical University, Russian Federation

Email: polouektova@rambler.ru

Russian Federation

кандидат медицинских наук, врач-гастроэнтеролог отделения хронических забо-
леваний кишечника и поджелудочной железы клиники пропедевтики внутренних болезней, гастроэнтерологии и
гепатологии им. В.Х. Василенко УКБ № 2 Первого МГМУ им. И.М. Сеченова
Адрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1

O. S. Shifrin

I.M. Sechenov First Moscow State Medical University, Russian Federation

Email: oleg_shifrin@mail.ru

Russian Federation

доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней
лечебного факультета Первого МГМУ им. И.М. Сеченова, заведующий отделением хронических заболеваний
кишечника и поджелудочной железы клиники пропедевтики внутренних болезней, гастроэнтерологии и гепато-
логии им. В.Х. Василенко УКБ № 2 Первого МГМУ им. И.М. Сеченова
Адрес: 119991, Москва, ул. Погодинская, д. 1, стр. 1

  1. Toh B.H. Diagnosis and classification of autoimmune gastritis. Auto-immun Rev. 2014; 13 (4–5): 459–462.
  2. Smyk D.S., Koutsoumpas A.L., Mytilinaiou M.G., Rigopoulou E.I., Sakkas L.I., Bogdanos D.P. Helicobacter pylori and autoimmune disease: cause or bystander. World J. Gastroenterol. 2014; 20 (3): 613–629.
  3. Varbanova M., Frauenschläger K., Malfertheiner P. Chronic gastritis an update. Best Pract. Res. Clin. Gastroenterol. 2014; 28 (6): 1031–1042.
  4. Whittingham S., Mackay I.R. Autoimmune gastritis: historical antecedents, outstanding discoveries, and unresolved problems. Int. Rev. Immunol. 2005; 24 (1–2): 1–29.
  5. Lee J.Y., Kim N., Lee H.S., Oh J.C., Kwon Y.H., Choi Y.J., Yoon K.C. Correlations among endoscopic, histologic and serologic diagnoses for the assessment of atrophic gastritis. J. Cancer Prev. 2014; 19 (1): 47–55.
  6. Polydorides A.D. Pathology and differential diagnosis of chronic, noninfectious gastritis. Semin Diagn. Pathol. 2014; 31 (2): 114–123.
  7. Vannella L., Lahner E., Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal. World J. Gastroenterol. 2012; 18 (12): 1279–1285.
  8. Egorov V.I., Karmazanovskii G.G., Shchegolev A.I. Autoimmune pancreatitis. Can the preoperative diagnosis? Klinicheskaya i eksperimental'naya gastroenterologiya = Clinical and experimental gastroenterology. 2007;6:13–20.
  9. Nishimori I., Tamakoshi A., Otsuki M. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. J. Gastroenterol. 2007; 42 (Suppl. 18): 6–8.
  10. Matsubayashi H., Kakushima N., Takizawa K., Tanaka M., Imai K., Hotta K., Ono H. Diagnosis of autoimmune pancreatitis. World J. Gastroenterol. 2014; 20 (44): 16559–16569.
  11. Asada M., Nishio A., Uchida K., Kido M., Ueno S., Uza N., Kiriya K., Inoue S., Kitamura H., Ohashi S., Tamaki H., Fukui T., Matsuura M., Kawasaki K., Nishi T. Watanabe N. Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis. Pancreas. 2006; 33 (1): 20–26.
  12. Frulloni L., Lunardi C., Simone R., Dolcino M., Scattolini C., Falconi M., Benini L., Vantini I., Corrocher R., Puccetti A. Identification of a novel antibody associated with autoimmune pancreatitis. N. Engl. J. Med. 2009; 361 (22): 2135–2142.
  13. Yamamoto M., Naishiro Y., Suzuki C., Kokai Y., Suzuki R., Honda S., Abe T., Takahashi H., Shinomura Y. Proteomics analysis in 28 patients with systemic IgG4 related plasmacytic syndrome. Rheumatol. Int. 2010; 30 (4): 565–568.
  14. Hart P.A., Zen Y., Chari S.T. Recent Advances in Autoimmune Pancreatitis. Gastroenterology. 2015; 148 (3). Doi: http://dx.doi. org/10.1053/j.gastro.2015.03.010.
  15. Chang M.C., Liang P.C., Jan S., Yang C.Y., Tien Y.W., Wei S.C., Wong J.M., Chang Y.T. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19–9 levels. Pancreatology. 2014; 14 (5): 366–372.
  16. Shimosegawa T., Chari S.T., Frulloni L., Kamisawa T., Kawa S., Mino-Kenudson M., Kim M.H., Kloppel G., Lerch M.M., Lohr M., Notohara K., Okazaki K., Schneider A. and Zhang L. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011; 40: 352–358.
  17. Chari S.T. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria. J. Gastroenterol. 2007; 42 (Suppl. 18): 39–41.
  18. Hart P.A, Kamisawa T., Brugge W.R., Chung J.B., Culver E.L., Czakó L., Frulloni L., Go V.L., Gress T.M., Kim M.H., Kawa S., Lee K.T., Lerch M.M., Liao W.C., Löhr M., Okazaki K., Ryu J.K., Schleinitz N., Shimizu K., Shimosegawa T., Soetikno R., Webster G., Yadav D., Zen Y., Chari S.T. Long term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013; 62 (12): 1771–1776.
  19. Huggett M.T., Culver E.L., Kumar M., Hurst J.M., Rodriguez-Jus-to M., Chapman M.H., Johnson G.J., Pereira S.P., Chapman R.W., Webster G.J., Barnes E. Type 1 autoimmune pancreatitis and IgG4 related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am. J. Gastroenterol. 2014; 109 (10): 1675–1683.
  20. Leishner U. Autoimmunnye zabolevaniya pecheni i perekrestnyi sindrom [Autoimmune Liver Disease and Cross Syndrome]. Moscow, Anakharsis, 2005. 54 p.
  21. Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.Ch., Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J. Hepatol. 2013; 58: 593–608.
  22. Yang F., Wang Q., Jia J., Ma X.J. Autoimmune Hepatitis: East Meets West. Gastroenterol. Hepatol. 2015; 30. doi: 10.1111/jgh.12952.
  23. Oo Y.H., Hubscher S.G., Adams D.H. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol. Int. 2010; 4 (2): 475–493.
  24. Couto C.A., Bittencourt P.L., Porta G., Abrantes–Lemos C.P., Carrilho F.J., Guardia B.D., Cançado E.L. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology. 2014; 59: 592–600.
  25. Gatselis N.K., Zachou K., Koukoulis G.K., Dalekos G.N. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinic-laboratory and histological characteristics. World J. Gastroenterol. 2015; 21 (1): 60–83.
  26. Manns, M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Verga- ni G., Vergani D., Vierling J.M. Diagnosis and management of autoimmune hepatitis. J. Hepatol. 2010; 51 (6): 2193–2213.
  27. Danielsson Borssén Å., Almer S., Prytz H., Wallerstedt S., Friis- Liby I.L., Bergquist A., Nyhlin N., Hultcrantz R., Sangfelt P., Weiland O., Lindgren S., Verbaan H., Werner M. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis a long term follow up study in 634 Swedish patients. Scand. J. Gastroenterol. 2015; 50 (2): 217–223.
  28. Corpechot C., Chretien Y., Chazouilleres O., Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J. Hepatol. 2010; 53 (1): 62–69.
  29. Muratori L., Granito A., Muratori P., Pappas G., Bianchi F.B. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin. Liver Dis. 2008; 12: 261–276.
  30. Kawata K., Kobayashi Y., Gershwin M., Bowlus Ch.L. The Immuno-physiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin. Rev. Allerg. Immunol. 2012; 43: 230–241.
  31. Lindor K.D., Gershwin M.E., Poupon R., Kaplan M., Bergasa N.V., Heathcote E.J. Primary biliary cirrhosis. Hepatology. 2009; 50 (1): 291–308.
  32. Mayo M.J. Natural history of primary biliary cirrhosis. Clin. Liver Dis. 2008; 12 (2): 277–288.
  33. Ivashkin V.T., Shirokova E.N., Maevskaya M.V., Pavlov Ch.S., Shifrin O.S., Maev I.V., Trukhmanov A.S. Clinical guidelines of the Russian Gastroenterological Association and the Russian Society for the Study of the Liver on the diagnosis and treatment of cholestasis. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii = Russian journal of gastroenterology, hepatology and colopractyology. 2015;25(2):40–55.
  34. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. European Association for the Study of the Liver. J. Hepatol. 2009; 51: 237–267.
  35. Lammers W.J., van Buuren H.R., Hirschfield G.M., Janssen H.L., Invernizzi P., Mason A.L., Invernizzi P., Mason A.L., Ponsioen C.Y. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow up study. Gastroenterology. 2014; 147 (6): 1338–1349.
  36. Rong G., Wang H., Bowlus C.L., Wang C., Lu Y., Zeng Z., Qu J., Lou M., Chen Y., An L., Yang Y., Gershwin M.E. Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis. Clin. Rev. Allergy Immunol. 2015; 48 (2): 132–141.
  37. Karlsen T.H., Boberg K.M. Update on primary sclerosing cholangitis. J. Hepatol. 2013; 59 (3): 571–582.
  38. Ali A.H., Carey E.J. and Lindor K.D. Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis. Res. 2015; 4 (1): 1–6.
  39. Eaton J.E., Talwalkar J.A., Lazaridis K.N., Gores G., Lindor K.D. Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management. Gastroenterology. 2013; 145 (3): 1–33.
  40. Poluektova E.A., Lyashenko O.S., Korolev A.V., Shifrin O.S., Ivashkin V.T. Mechanisms for the interaction of the bacterial cells with the host, and their disorder in patients with inflammatory bowel diseases. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii = Russian journal of gastroenterology, hepatology and colopractyology. 2014;24(5):42–53.
  41. Johansson M.E., Larsson J.M., Hansson G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host microbial interactions. Proc. Natl. Acad. Sci. USA. 2011; 108: 4659–4665.
  42. Sandborn W., Rogler G. The Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology. Peprint of Digestive Disease. 2010; 28 (3): 385–568.
  43. Baumgart D.C. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch. Arztebl. Int. 2009; 106 (8): 123–133.
  44. Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R., Mitton S., Orchard T., Rutter M., Younge L., Lees C., Ho G.T., Sat-sangi J., Bloom S. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60 (5): 571–607.
  45. Magro F., Langner C., Driessen A., Ensari A., Geboes K., Mantza- ris G.J., Villanacci V., Becheanu G., Borralho Nunes P., Cathomas G., Fries W., Jouret–Mourin A., Mescoli C., de Petris G., Rubio C.A., Shepherd N.A., Vieth M., Eliakim R. European consensus on the histopathology of inflammatory bowel disease. J. Crohn’s Colitis. 2013; 7 (10): 827–851.
  46. Ivashkin V.T., Shelygin Yu.A., Abdulganieva D.I., Abdulkhakov R.A., Alekseeva O.P., Achkasov S.I., Baranovskii A.Yu., Belousova E.A., Golovenko O.V., Grigor'ev E.G., Kostenko N.V., Lapina T.L., Maev I.V., Moskalev A.I., Nizov A.I., Nikolaeva N.N., Osipenko M.F., Pavlenko V.V., Parfenov A.I., Poluektova E.A., Rumyantsev V.G., Timerbulatov V.M., Tertychnyi A.S., Tkachev A.V., Trukhmanov A.S., Khalif A.L., Khubezov D.A., Chashkova E.Yu., Shifrin O.S., Shchukina O.B. Recommendations of the Russian Gastroenterological Association and the Association of Russian Coloproctologists for diagnosis and treatment of adult patients with ulcerative colitis. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii = Russian journal of gastroenterology, hepatology and colopractyology. 2015;25(1):48–65.
  47. Dignass A., Eliakim R., Magro F., Maaser Ch., Chowers Y., Geboes K., Mantzaris G., Reinisch W., Colombel J.F., Vermeire S., Travis S., Lindsay J.O., Van Assche G. Second European evidence based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J. Crohn's Colitis. 2012; 6 (10): 965–990.
  48. Sands B.E. New drugs on the horizon for IBD. Dig. Dis. 2014; 32 (Suppl. 1): 74–81.
  49. Bohr J., Wickbom A., Hegedus A., Nyhlin N., Hultgren H.E., Tysk C. Diagnosis and management of microscopic colitis: current perspectives. Clin. Exp. Gastroenterol. 2014; 7: 273–284.
  50. Schuppan D., Zimmer K.P. The diagnosis and treatment of celiac disease. Dtsch. Arztebl. Int. 2013; 49 (49): 835–846.
  51. Ludvigsson J.F., Bai J.C., Biagi F., Card T.R., Ciacci C., Ciclitira P.J., Green P.H., Hadjivassiliou M., Holdoway A., van Heel D.A., Kaukinen K., Leffler D.A., Leonard J.N., Lundin K.E., McGough N., Davidson M., Murray J.A., Swift G.L., Walker M.M., Zingone F., Sanders D.S. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014; 63 (8): 1210–1228.
  52. Pelkowski T.D., Viera A.J. Celiac disease: diagnosis and management. Am. Fam. Physician. 2014; 89 (2): 99–105.

Views

Abstract - 84

PDF (Russian) - 321

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.